RecruitingPhase 3

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

United States400 participantsStarted 2026-02-04

Plain-language summary

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria
✓. Measurable disease at screening as assessed by central laboratory

What they're measuring

Overall Response Rate (ORR)

Timeframe: Up to 5 years and 4 months

Progression-Free Survival (PFS)

Timeframe: Up to 5 years and 4 months

Trial details

NCT IDNCT07258511

SponsorJanssen Research & Development, LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-12-12

Contact for this trial

Study Contact

844-434-4210 Participate-In-This-Study1@its.jnj.com

View on ClinicalTrials.gov More Multiple Myeloma trials